Arena Pharmaceuticals raised its stocks value as well as hope for patients suffering from the rare lung disease that its experimental drug Ralinepag should help to cure.
As soon as the company has annouced the positive results in phase 2 for the experimental drug Ralinepag, share went up more than 44%.
The drug so far met its primary Phase 2 program goal as patients with pulmonary arterial hypertension showed a meaningful improvement in the conditions as well as greater pulmonary vascular resistance.
“These data give us confidence to move expeditiously toward a Phase 3 clinical program,” Arena chief medical officer Preston Klassen said.ù
Source: CBNC
